Michael's Shared Resources
FDA Accepts New Drug Application for Xanomeline-Trospium
Karuna Therapeutics announced that the FDA accepted their New Drug Application for KarXT (xanomeline-trospium), a treatment for schizophrenia in adults...
Michael Asbach,
DMSc, PA-C, Psych-CAQ
Associate Director, Interventional Psychiatry, DENT Neurologic Institute
Associate Director, Interventional Psychiatry, DENT Neurologic Institute
Danish Study Finds Higher Schizophrenia Risk in Young Males With Cannabis Use Disorder
In a study, researchers focused on the relationship between cannabis use disorder (CUD) and schizophrenia, particularly in males. It was...
Michael Asbach,
DMSc, PA-C, Psych-CAQ
Associate Director, Interventional Psychiatry, DENT Neurologic Institute
Associate Director, Interventional Psychiatry, DENT Neurologic Institute
“My 2-Minute Neuroscience” Video Explores Schizophrenia’s Complex Neurobiology
A recent two-minute video touches on the Neuroscientific research on schizophrenia that has mainly focused on neurotransmitter abnormalities, particularly dopamine,...
Michael Asbach,
DMSc, PA-C, Psych-CAQ
Associate Director, Interventional Psychiatry, DENT Neurologic Institute
Associate Director, Interventional Psychiatry, DENT Neurologic Institute
New Promising Drugs in Schizophrenia Treatment Discussed by Expert Roundtable
An expert roundtable discussed various promising drugs with novel mechanisms, such as ulotaront (a TAAR1 agonist and 5-HT1A agonist) from...
Michael Asbach,
DMSc, PA-C, Psych-CAQ
Associate Director, Interventional Psychiatry, DENT Neurologic Institute
Associate Director, Interventional Psychiatry, DENT Neurologic Institute
Schizophrenia Treatments Target Muscarinic Receptors, Promising Personalized Approaches
A study emphasized the importance of muscarinic M1 and M4 receptors in treating schizophrenia, with new medications like KarXT and...
Michael Asbach,
DMSc, PA-C, Psych-CAQ
Associate Director, Interventional Psychiatry, DENT Neurologic Institute
Associate Director, Interventional Psychiatry, DENT Neurologic Institute
Machine Learning Improves Schizophrenia Diagnosis
In a recent study involving 72 schizophrenia patients and 74 healthy control subjects using structural magnetic resonance imaging data, various...
Michael Asbach,
DMSc, PA-C, Psych-CAQ
Associate Director, Interventional Psychiatry, DENT Neurologic Institute
Associate Director, Interventional Psychiatry, DENT Neurologic Institute